CLAIMS

1. A combination suitable for use in treating cancer, comprising (*S*)-4-amino-*N*-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)piperidine-4-carboxamide, or a pharmaceutically acceptable salt thereof, and a taxane, wherein the (*S*)-4-amino-*N*-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)piperidine-4-carboxamide and the taxane are adapted for sequential administration wherein the taxane is administered prior to administration of the (*S*)-4-amino-*N*-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)piperidine-4-carboxamide within a dosage cycle.

2. The combination according to claim 1 wherein the combination comprises (*S*)-4-amino-*N*-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)piperidine-4-carboxamide and a taxane.

3. The combination according to claim 1 or claim 2 wherein the taxane is selected from docetaxel, paclitaxel, cabazitaxel, larotaxel, ortataxel and tesetaxel.

4. The combination according to claim 3 wherein the taxane is selected from docetaxel and paclitaxel.

5. A combination according to any one of claims 1 to 4 for use as a medicament.

6. A combination according to any one of claims 1 to 4 for use in the treatment of cancer.

~~7. A pharmaceutical composition which comprises a combination as claimed in any one of claims 1 to 4, in association with a pharmaceutically acceptable diluent or carrier.~~

~~8.~~7. A pharmaceutical product suitable for use in treating cancer, comprising:

(i) a pharmaceutical composition which comprises (*S*)-4-amino-*N*-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)piperidine-4-carboxamide, or a pharmaceutically acceptable salt thereof,~~Compound (I)~~ in association with a pharmaceutically acceptable diluent or carrier; and

(ii) a pharmaceutical composition which comprises a taxane in association with a pharmaceutically acceptable diluent or carrier;

wherein the (*S*)-4-amino-*N*-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)piperidine-4-carboxamide and the taxane are adapted for sequential administration wherein the taxane is administered prior to administration of the (*S*)-4-amino-*N*-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)piperidine-4-carboxamide within a dosage cycle.

~~9.~~8. The pharmaceutical product as claimed in claim 78 wherein the taxane is selected from docetaxel and paclitaxel.

~~10.~~9. The pharmaceutical product as claimed in claim 7~~8~~ or claim 8~~9~~ for use in the treatment of cancer.

~~11.~~10. The pharmaceutical product as claimed in claim 7~~8~~ or claim 8~~9~~ for use in the treatment of breast cancer.

~~12.~~11. A kit comprising (*S*)-4-amino-*N*-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)piperidine-4-carboxamide, or a pharmaceutically acceptable salt thereof, ~~and~~ a taxane,~~; optionally with~~ and instructions for use in treating cancer by administering the taxane prior to administering the(*S*)-4-amino-*N*-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)piperidine-4-carboxamide within a dosage cycle.

~~13.~~12. The kit according to claim 11~~12~~ wherein the taxane is selected from docetaxel and paclitaxel.

~~14. A method of treating cancer, in a warm-blooded animal, such as man, which comprises administering to said animal an effective amount of (*S*)-4-amino-*N*-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)piperidine-4-carboxamide, or a pharmaceutically acceptable salt thereof, in combination with an effective amount of a taxane.~~

~~15. The method according to claim 14 wherein the taxane is selected from docetaxel and paclitaxel.~~

~~16. The method according to either claim 14 or claim 15, wherein the cancer is breast cancer.~~

~~17.~~13. Use of (*S*)-4-amino-*N*-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)piperidine-4-carboxamide, or a pharmaceutically acceptable salt thereof,~~Compound (I)~~, in combination with a taxane in the manufacture of a medicament for the treatment of cancer, wherein said treatment comprises administration of the taxane prior to administration of the (*S*)-4-amino-*N*-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)piperidine-4-carboxamide, or a pharmaceutically acceptable salt thereof, within a dosage cycle.~~.~~

~~18.~~14. Use according to claim 13~~17~~ wherein the taxane is selected from docetaxel and paclitaxel.

~~19.~~15. Use according to claim 13 ~~17~~ or claim 14 ~~18~~ wherein the cancer is breast cancer.

~~20.~~16. The use according to any one of claims ~~17~~ 13 to ~~19~~ 15 wherein the taxane is only dosed within the 1 day prior to the first dosing of the (*S*)-4-amino-*N*-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)piperidine-4-carboxamide, or a pharmaceutically acceptable salt thereof,~~Compound (I)~~ within a given dosage cycle.

~~21.~~17. The use according to claim ~~20~~ 16 wherein the dosage cycle involves (*S*)-4-amino-*N*-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)piperidine-4-carboxamide, or a pharmaceutically acceptable salt thereof,~~Compound (I)~~ being dosed for 3-4 consecutive days and not being dosed for the other days within a dosage cycle of 6 to 9 days in length.

~~22.~~18. The use according to claim ~~20~~ 16 or ~~21~~ 17 wherein the taxane is dosed at 50-140mg/m^2 of patient surface area on the day(s) when it is dosed.

~~23.~~19. The use according to any one of claims ~~20~~ 16 to ~~22~~ 18 wherein the (*S*)-4-amino-*N*-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)piperidine-4-carboxamide~~the AZD5363 content of Compound (I)~~ is dosed to the patient at 200-500mg per day on the days when it is dosed.